The new BD syringe is presently in development and will undergo comprehensive testing to ensure its compatibility with Ypsomed’s YpsoMate 5.5 autoinjector platform. Syringe samples for feasibility studies are expected to be available in mid-2026. During the same time period, Ypsomed will expand its YpsoMate 5.5 platform and integrate the BD Neopak XtraFlow 5.5ml glass prefillable syringe.
The goal is to broaden options for pharmaceutical companies and patients who require large‑volume subcutaneous self‑injections, which have become more common in the biologics space. The collaboration builds on the companies’ work with the BD Neopak XtraFlow 2.25ml glass prefillable syringe and YpsoMate 2.25 autoinjector.
The new 5.5ml BD Neopak XtraFlow glass prefillable syringe leverages BD technologies including a shorter, 8-mm needle and thinner wall cannulas, to support the delivery of higher volume and viscosity medicines. These enhancements should enable improved injection time and optimized flow, addressing common challenges with large-volume biologics and enabling drug developers to move beyond the limitations of standard syringe offerings, according to the companies.
“This next generation syringe is a direct response to the growing demand for patient-friendly solutions in the high-dose biologics space,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems, in a news release yesterday. “By combining BD’s expertise in drug delivery with Ypsomed’s leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions.”
Meeting the needs of biologics innovation
Large‑volume (greater than 1 ml) subcutaneous injections of biologics have become increasingly common in areas such as oncology, autoimmune diseases, rare diseases, and metabolic disorders, according to the companies.
Ypsomed’s YpsoMate 5.5, introduced in 2022, was meant to offer large-volume injection needs, offering an ergonomic design, intuitive two‑step activation, and clear feedback to support patient confidence and ease of use.
The new BD Neopak XtraFlow 5.5ml glass prefillable syringe will further enhance the YpsoMate 5.5 platform by maximizing flow efficiency and reducing injection time, which are important factors as dosing volumes and drug viscosities continue to rise.
“Ypsomed and BD, in close collaboration with our pharmaceutical partners, are expanding the subcutaneous delivery design space to accommodate high-dose therapies, both volume and viscosity,” said Ulrike Bauer, chief business officer at Ypsomed. “These partnerships are critical as we jointly drive the future of high-dose biopharmaceutical delivery.”
